Maipl Therapeutics develops small molecule new drugs to treat cancer, endometriosis, and idiopathic pulmonary fibrosis (IPF). The company’s platform is based on breakthrough FP antagonist (FPA) lead compounds licensed from Ferring Pharmaceuticals. The FPA leads are potent and highly selective inhibitors of prostaglandin F2α signaling. One of them, MA-7107, is being developed as a liver cancer therapy that augments chemo, radiation, or immunotherapies to improve survival or overcome resistance. We are also developing other FPA assets for indications in which elevated F2α signaling is a driver. FPAs have virtually no impact on other essential prostaglandin functions, thus are expected to safer than NSAIDs and COX-2 which are associated with rare but serious GI, renal, and CV side effects. Maipl aims to file IND submissions in 1-2 years and maintain its first-mover advantage.